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Parkinson’s disease (PD) has been associated with exposure to a variety of environmental agents, including pesticides, heavy
metals, and organic pollutants; and inﬂammatoryprocesses appear to constitute a common mechanistic link amongthese insults.
Indeed, toxin exposure has been repeatedly demonstrated to induce the release of oxidative and inﬂammatory factors from
immunocompetent microglia,leading to damage and death of midbrain dopamine (DA) neurons. In particular, proinﬂammatory
cytokines such as tumor necrosis factor-α and interferon-γ, which are produced locally within the brain by microglia, have
been implicated in the loss of DA neurons in toxin-based models of PD; and mounting evidence suggests a contributory role
of the inﬂammatory enzyme, cyclooxygenase-2. Likewise, immune-activating bacterial and viral agents were reported to have
neurodegenerative eﬀects themselves and to augment the deleterious impact of chemical toxins upon DA neurons. The present
paper will focus upon the evidence linkingmicroglia and their inﬂammatoryprocesses to the death ofDA neurons followingtoxin
exposure. Particular attention will be devoted to the possibility thatenvironmental toxins can activate microglia,resulting in these
cells adopting a “sensitized” state that favors the production of proinﬂammatorycytokines and damaging oxidative radicals.
1.Introduction
Parkinson’s disease (PD)is themost commonneurodegener-
ative disorder of motor functioning, aﬀecting nearly six mil-
lion people worldwide. The disorder is particularly prevalent
in the elderly population, with a typical clinical onset after
60−65 years of age. Notwithstanding the rare familial forms
of PD that appear to have a strong genetic component, the
vast majority of PD cases (upwards of 90%) are idiopathic in
nature. Regardless of etiology, PD is characterized primarily
by the progressive degeneration of dopamine (DA) neurons
within the substantia nigra pars compacta (SNc) region
of the midbrain, resulting in the diminished monoamine
release at downstream striatal nerve terminals. Clinically,
the Parkinsonian syndrome, which typically becomes man-
ifest following 50−60% SNc DA neuron loss, comprises a
constellation of well-deﬁned motor symptoms, including
bradykinesia, hypokinesia (or akinesia), cogwheel rigidity,
resting tremor, and postural instability [1]. In addition to
the motor impairment evident in all PD cases, a substantial
number of PD patients also display prominent “nonmotor”
symptoms (many of which manifest before the onset of
motor decline and PD diagnosis), including autonomic and
olfactory problems (e.g., sleep disorders, hyposmia), as well
as cognitive and psychological disturbances (e.g., anxiety,
depression)[2].Whilestriatal DAdenervationmayinﬂuence
the development of at least some of these symptoms (e.g.,
memory and attention problems [3]), it is likely that multi-
neurotransmitter dysfunction in brain regions important
for autonomic, emotional and psychological functioning
(e.g., locus coeruleus, prefrontal cortex, hippocampus) is
important in this regard (perhaps stemming from parallel
inﬂammatory and neurodegenerative processes) [4, 5].
Epidemiological studies have implicated exposure to
pesticides and other potential environmental toxins (e.g.,
heavy metals and even immune infections) in the evolution
of PD [6, 7]. Parallel work in rodents has likewise revealed
that administration of certain pesticides, most notably2 Parkinson’s Disease
paraquat and rotenone, recapitulates many of the character-
istic neuropathological and behavioral features of PD [8, 9].
Over the past few decades it has become clear that neuroin-
ﬂammatory factors, including proinﬂammatory cytokines
produced by glial cells, are involved in many aspects of the
neurodegenerative process in PD. Indeed, manipulation of
cytokines and associated inﬂammatory signaling pathways
was reported to aﬀect DA neuronal survival in response to
ah o s to fd i ﬀerent toxins [10, 11]. Moreover, alterations of
microglial cell reactivity have been routinely demonstrated
during early and late phases of the degenerative process in
animalmodelsofPD[12,13].Correspondingly,postmortem
PD brains typicallydisplay signs of heightenedinﬂammatory
and oxidative distress, including increased proinﬂammatory
cytokines and microglial activation [14, 15], as well as
augmented oxidative and inﬂammatory enzyme expres-
sion (e.g., nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase, inducible nitric oxide synthase (iNOS),
cyclooxygenase-2 (COX-2)) [16, 17].
Substantial recent interest has focused on microglial
cells as potential mediators of pathology in PD; however, it
remains to be determined whether these cells are primary
players in disease progression or are secondarily recruited
following damage. Alternatively, it might be the case that
microglia are involved in all stages of PD but that their
role changes (e.g., neuroprotective versus neurodestructive)
as the disease progresses through diﬀerent stages. Indeed,
during normal physiological conditions microglial cells
are constantly detecting and reacting to modiﬁcations in
their local environment and attempting to maintain proper
tissue homeostasis [18, 19]. When suﬃciently stressed by
insults, neurons release ATP into the extracellular space and
microglia migrate along these ATP gradients and facilitate
the removal of the dead/sick cells through phagocytosis
[18, 20]. However, in the case of PD, these “danger” signals
released from injured and dying cells (e.g., ATP, heat-shock
proteins)may besubtleand occuroveraprolongedperiodof
time [21], essentially placing microglia in a chronically active
state.
The reactivity state of microglia varies along a spectrum
ranging from resting to hyperactive and is under the strict
control of several regulatory proteins [22]. Some evidence
suggests that microglial cells can perform neuroprotective
functions in PD, at least in the short term, by secreting
trophic factors such as nerve growth factor, neurotrophin-
3 and brain-derived neurotrophic factors (BDNFs) [23, 24].
However, as the disease progresses, there is compelling
evidencetoindicatethatmicroglia undergosigniﬁcant eleva-
tionsin cell surface activation/adhesion moleculesand adopt
a more hyperactive state that is morphologically similar
to peripheral macrophages [25]. In this state, microglia
are capable of upregulating the synthesis and release of a
host of proinﬂammatory and prooxidant factors, including
cytokines, prostaglandins (PGs) and reactive oxygen species
(ROS) [26]. Indeed, following toxin exposure, chronically
activated microglia can produce large quantities of superox-
ide (e.g., via the NADPH oxidase enzyme), which, in turn,
c a nl e a dt ot h ed a m a g ea n dd e a t ho fa d j a c e n tD An e u r o n s
[27, 28].
The present paper will, (1) cover the evidence linking
exposure to environmental toxins and the development of
PD; (2) review the mechanisms by which inﬂammatory
cytokines aﬀect central nervous system (CNS) functioning;
and (3) evaluate the possibility that cytokines and inﬂam-
matory and oxidative enzymes are involved in the PD-like
neurodegenerative process induced by environmental toxins.
2.EnvironmentalToxinExposureandPD
Although familial forms of PD are relatively rare, certain
genetic mutations have been reported to enhance susceptibly
to environmental insults and hence, might contribute to
the more common idiopathic cases of the disease. In
fact, a recent study revealed that individuals possessing a
combination of mutations of the DA transporter (DAT) and
who had substantial life-long pesticide exposure were at
greater risk for developing PD than individuals with either
the genetic factor or pesticide exposure alone [6]. Moreover,
the recent ﬁndings that polymorphism within certain envi-
ronment responsive genes encoding eﬀector proteins critical
for cellular detoxiﬁcation and xenobiotic metabolism (e.g.,
CYP2D64, GSTT1 and P1) modiﬁed the risk of developing
PD, suggests that environmental toxicants might contribute
toPDingeneticallyvulnerableindividuals[29,30].However,
another report indicated that pesticide exposure was a
signiﬁcant predictorofPDincidenceamong individualswith
a negative family history but not those with a positive family
history of the disease [31]. In eﬀect, it is likely that the role
of genetics depends upon the particular “subtype” of PD.
Indeed, PD appears to be a highly heterogeneous disorder
with corresponding heterogeneity in etiological origins.
Whereas autosomal dominant/recessive familial forms of PD
(e.g., LRRK2, DJ-1, Parkin) appear to be at one end of the
spectrum, purely environmental “toxic exposure” cases may
represent the other end. Hence, the bulk of “idiopathic”
PD cases falls in the middle and will likely involve a mix
of genetic and environmental inﬂuences. Indeed, there is
a very low penetrance of LRRK2 heterozygotic carriers
that actually express the PD phenotype; yet, a signiﬁcant
proportion of PD patients carry a LRRK2mutation, suggest-
ing that such genes might be seen as susceptibility factors
[32].
While genetic vulnerability may be seen as providing a
backdrop for disease provocation, several compelling lines
of evidence suggest that environmental agents, including
commonly used pesticides, can act as triggers for the devel-
opment of PD. In fact, a progressively greater odds ratio for
developing PD was associated with pesticide exposure [6],
and several other epidemiological studies have implicated
speciﬁc pesticides, including rotenone (an organic insecti-
cide) and paraquat (a chemical herbicide still widely used
throughout the world), in the development of parkinsonism
[33, 34]. Indeed, a sharp increase of PD incidence was
seen in agricultural areas that use these pesticides [35, 36].
In particular, the nonselective herbicide, paraquat (N,N
 -
dimethyl-4,4 -bipyridylium ion), signiﬁcantly augmented
the risk of developing PD as a function of cumulative
pesticide exposure [37].Parkinson’s Disease 3
Animal studies also demonstrate that the pesticides,
paraquat and rotenone, which are chemically similar to
the established DA neurotoxin, MPTP, can reliably induce
PD-like pathology, and hence, are becoming widely used
to produce a parkinsonian syndrome in animals. Indeed,
systemic exposure to paraquat provoked a dose-dependent
loss of DA neurons in the SNc [8, 38], coupled with a
reduction in the density of striatal DA ﬁbres expressing
tyrosine hydroxylase, therate-limiting enzyme inDAsynthe-
sis [39]. The pesticide was also shown to diminish striatal
DA concentration and to reproduce certain aspects of the
PD phenotype in rodents (bradykinesia, motor coordination
deﬁcits, depressive-like symptoms, memory impairment)
[39–43]. However, it is worth noting that the impact of
paraquat upon the striatum appears to be somewhat less
pronounced than the eﬀects of the pesticide upon SNc DA
neuronal soma [44]. As well, some authors have failed to
ﬁnd changes in striatal DA levels or behavioral impairment,
evenin thepresence oflossofDAsoma [45].Itis conceivable
that compensatory downstream processes provoked by soma
loss (e.g., changes in dendritic branching patterns, up-
regulation of proneuroplastic peptides or neurotrophins,
or alterations of brain monoamine systems) could account
for such discrepancies between SNc pathology and striatal
functioning. Also, variations in experimental design (e.g.,
route of administration, dosing regimen, sacriﬁce interval,
striatal subregions tested, age of mice) probably contribute
to some of the inconsistency in ﬁndings across studies
[46–48].
Of course, paraquat is not alone in producing sometimes
discrepant research ﬁndings, as virtually all of the most
common toxin models of PD have engendered controversy
with respect to selective DA neuron loss, variable striatal DA
depletion and behavioral impairment, and/or the generation
of Lewy body-like α-synuclein inclusions (see Table 1)[ 49–
51]. Of these PD mimetics, MPTP is perhaps the most
widely used and well characterized, producing consistent
andreproduciblePD-likepathologyinseveralanimal species
(e.g., DA lesion, reactive microgliosis, motor deﬁcit). Yet,
pesticides such as paraquat and rotenone, in addition to
having greater ecological relevance than the MPTP model of
PD, have been shown to provoke histopathological changes
that more closely resemble the disease, particularly the
depositionofα-synuclein aggregates in neuronal Lewy body-
like inclusions (see Table 1)[ 9, 52, 53]. In fact, Drolet
and colleagues [54] recently found that rats treated with
systemic rotenone displayed marked α-synuclein pathology
in small intestine myenteric neurons that was reminiscent
of the enteric Lewy body pathology commonly seen in
PD patients. Moreover, it was reported that exposure
to certain combinations of heavy metals and pesticides
may synergistically provoke conformational changes in α-
synuclein, favoring the development of PD-like pathology
[55]. In fact, recent work revealed that exposure to a
combination of iron and paraquat synergistically increased
α-synuclein aggregation and ﬁbrillization, and augmented
the extent of microglia-induced oxidative stress and neu-
rodegeneration [56, 57]. Similarly, although the dithiocar-
bamate pesticide, maneb, had no eﬀect on SNc DA neurons
alone, when coadministered with paraquat it synergistically
enhanced nigrostriatal damage and associated glial reactivity
[58].
Pesticides can adversely aﬀect neuronal survival by
impairing mitochondrial functioning and overstimulating
microglial cells, causing an accumulation of oxidative free
radicals (e.g., superoxide, hydroxyl radicals) and inﬂam-
matory factors (particularly cytokines). Indeed, as will
be discussed in ensuing sections, we and others showed
that paraquat and rotenone enhanced the expression of
proinﬂammatory cytokines and elicited oxidative-nitrosative
stress through activation of the microglial inﬂammatory
enzyme, NADPH oxidase. In fact, as was reported for MPTP
[27], paraquat was demonstrated to preferentially damage
midbrain DA neurons through direct microglial-dependent
NADPH oxidase activity in neuron-microglia cultures [59].
However, the role of microglia is not without controversy,
with one recent report indicating that neither rotenone nor
paraquat directly activated cultured microglia (in terms of
morphology, nitric oxide synthesis and cytokine release)
[60]. Similarly, accumulating evidence suggests that the PG
synthase, COX-2, may contribute to the neurodegenerative
eﬀects of numerous DA toxins.
3. Inﬂammatory Cytokines in Relationto
CentralNervousSystemFunctioning
Until fairly recently the brain was believed to function more
or less independently of the immune system. However, it is
now accepted that circulating T lymphocytes, macrophages
and otherperipheral immune cellsroutinely entercerebrum,
albeit in limited concentrations, and perform a variety
of “housekeeping” tasks that are essential for immuno-
surveillance of the CNS [61] .T h ec o n v e r s ei sa l s ot r u e
in that changes in neural transmission, such as those
provoked by drug administration, can aﬀect immune cell
activity in the periphery. Yet, it should be noted that the
blood brain barrier (BBB), as well as several endogenous
inhibitory and apoptotic mechanisms operating within the
brain itself, normally tightly regulate the transmigratory
ﬂow of immune factors into the CNS, and how long they
persist therein. For instance, immune cells entering the
brain typically are removed or die via apoptosis relatively
rapidly; this is essential since postmitotic neurons are
especially sensitive to immune attack. However, increasing
evidence indicates that a range of neurological diseases,
including Amyotrophic Lateral Sclerosis, Alzheimer’s dis-
ease (AD) and PD have a prominent neuroinﬂammatory
component, involving increased inﬁltration of immune
cells, coupled with activation of resident brain glial cells
[17, 62].
Nonetheless, it should be underscored that not all CNS
inﬂammation is uniformly “bad”; indeed, transient neuroin-
ﬂammatory responses are a natural consequence of injury
or infection and may actually preserve viable brain tissue
in a manner analogous to a short-lived immune response
in the periphery (e.g., removal of cellular debris, release of
trophic factors) [63, 64]. Moreover, neuronal degeneration
itself provokes secondary inﬂammation that may or may not4 Parkinson’s Disease
Table 1: A comparison of some of the most commontoxin-based animal models of Parkinson’s disease.
Toxin
model Mode of action Advantages Disadvantages
6-OHDA
(i) DAT substrate
(ii) Cytotoxic quinone and ROS
formation
(i) Full DA depletion
(ii) Mimics late-stage PD
(i) Does not cross BBB
(ii) DA degeneration is not progressive
(iii) No Lewy body-like inclusions
(iv) Lacks external validity
MPTP
(i) Converted into MPP+
(ii) DAT substrate
(iii) Inhibits mitochondrial complex I
(iv) Strong inﬂammatory component
(i) Highly reproducible
(ii) Induces substantial DA loss and
motor impairment
(i) DA degeneration is not progressive
(ii) Does not provoke Lewy body-like
inclusions
(iii) Systemic toxicity
(iv) Lacks external validity
Paraquat (i) Potent redox cycler
(ii) Neuroinﬂammatory component
(i) Progressive loss of DA neurons
(ii) Lewy-body like α-synuclein
inclusions
(iii) Potential ecological validity
(i) Inconsistent striatal DA loss and
motor impairment
(ii) Induces only moderate DA cell loss
when administered alone
(ii) Systemic toxicity
Rotenone
(i) Readily crosses DA neuron
membrane
(ii) Inhibits mitochondrial complex I
(iii) Neuroinﬂammatory component
(i) Progressive loss of DA neurons
(ii) Lewy body-like inclusions
(iii) Potential ecological validity
(i) Variable reproducibility
(ii) Systemic toxicity
(iii) Nonspeciﬁc accumulation within the
CNS
LPS Immune system activation
(i) Progressive loss of DA neurons
(ii) Strong inﬂammatorycomponent
(iii) Sensitizes DA neurons to later
treatment with LPS or other toxins
No Lewy body-like inclusions
come to inﬂuence the primary degenerative process. Thus,
it is diﬃcult to assign valence to neuroinﬂammatory events
occurring in the PD brain on the basis of clinical autopsy
studies alone. In this context, toxin-based animal models
of PD provide a suitable and ecologically relevant means
of assessing the role and disease-modulating capability of
inﬂammatory responsesthatareeithermountedorsustained
by the CNS.
In addition to the inﬁltration of immune cells into the
brain parenchyma, substantial evidence has revealed that
immune factors can inﬂuence CNS functioning through
activation of receptors located on peripheral organs or
the BBB. These can, in turn, promote second messen-
ger cascades or stimulate neural aﬀerents that innervate
the CNS [65]. Indeed, one of the primary mechanisms
facilitating neuroimmune communication is the release of
soluble glycoprotein messengers called cytokines. Although
cytokinesare typically produced by peripheral immune cells,
evidence in recent decades has also convincingly uncovered
their production from CNS glial cells [66]. In particular,
immunocompotent microglia produce several cytokines and
bear receptors for these immunotransmitters, which can act
locally in an autocrine or paracrine manner to regulate func-
tioning of the originating or neighboring cells, respectively
[67].
The list of polypeptides that comprise the rapidly
growing family of cytokine immunotransmitters include;the
interferons (IFN), interleukins (IL), tumor necrosis factors
(TNF),chemokines (subclass of chemoattractant cytokines),
andgrowthandcellstimulatingfactors.Historically,theclas-
siﬁcation of cytokines has been based upon their molecular
structure, as well as common physiological actions they
possess, including the production of inﬂammation (i.e.,
swelling and irritation resulting from leukocyte inﬁltra-
tion) or fever (pyrogenicity) [67]. IL-1β,T N F - α and IL-
6, which are all released from activated macrophages, are
potent proinﬂammatory cytokines, whereas IL-4 and IL-
10, which are released from T-cells, have antiinﬂammatory
actions.
Cytokines may gain entry to the brain through sites
where the BBB is somewhat compromised (i.e., areas with
fewer or less complex tight junctions), namely at circum-
ventricular organs such as the median eminence and area
postrema [65]. As well, saturable carrier-mediated transport
mechanisms capable of moving IL-1β and TNF-α may allow
for limited penetration of cytokines into the brain [68, 69].
Once cytokines gain entry to the brain, they interact with
receptors on cells lining the BBB, around the meninges, as
well as at vascular areas of the brain [70]. Through volume
diﬀusion, inﬁltrating cytokines may ultimately penetrate
deep within the brain parenchyma [71, 72]w h e r et h e yc a n
inﬂuence, among other things, neuronal Ca2+ channels and
MAP kinase and COX-2 signaling [73, 74].
Pro- and- antiinﬂammatory cytokine levels are markedly
increased by immune and traumatic insults [75]. In this
regard, endothelial cells that line the interior surface of
blood vessels and the brain ventricles produce IL-1β and
IL-6, and infection or injury augments their concentration
[76]. Further, microglia, which serve as the brain’s own
specialized immune cells, are primary cytokine producers,
and the synthesis of these cytokines was augmented by head
injury, stroke and neurotoxins [77–79].Parkinson’s Disease 5
4.NeuroinﬂammatoryMechanisms ofPD:
Microglia, Cytokines,and
Inﬂammatory Enzymes
Systemic infection may interact with environmental insults
to induce exaggerated neuroinﬂammatory, degenerative and
behavioural changes in neurological patients [80]. Indeed,
exposure to pathogens or cytokines might have especially
marked CNS consequenceswhen encountered in the context
of concomitant chemical toxin, traumatic head injury, or
psychologicalstressorexposure,eachofwhichcancontribute
to a breakdown of the BBB, hence favoring entry of periph-
eral immune pathogens into the CNS. In this regard, the
bacterial endotoxin, LPS, synergistically augmented DA loss
in midbrain-microglia cocultures exposed to pesticides, such
as rotenone[81]a n dt h e s ee ﬀectsmay berelated toenhanced
NADPH oxidase-mediated release of the superoxide radical
[27]. Our own work has similarly shown that a low dose
of LPS enhanced the neurotoxic eﬀects of the herbicide,
paraquat, such that a substantial number of DA-producing
neurons were destroyed (i.e., more than was observed with
paraquat alone) and PD-like symptoms emerged [82]. The
augmented neurodegenerative response was observed when
paraquat administration occurred at a time of maximal
LPS-induced microglial activation (after 2 days), suggest-
ing that the inﬂammatory priming sensitized microglial
responding, thereby contributing to the degenerative eﬀects
of later paraquat exposure. Importantly, although relatively
high concentrations of LPS alone had neurodegenerative
consequences on DA neurons [83, 84], our studies involved
relatively low concentrations of the endotoxin that alone
activated microglia but had no eﬀect upon DA neuronal
survival.
The possibility exists that environmental or inﬂam-
matory toxins might promote a sensitization of neuronal
processes across the lifespan, such that exposure to an
immune/chemical toxin at one point in life enhances vul-
nerability to the behavioural and neurodestructive eﬀects
of these challenges when subsequently encountered months
or even years later. In particular, at in utero and early life
stages when neuronal migration and synaptic pruning are
occurring, neurons are especially sensitive to perturbations
caused by environmental agents. Atthe same time, biological
detoxiﬁcation systems involved in metabolism and clearance
of toxic substances are not fully developed in fetuses, infants
and young children. Indeed, prenatal exposure to LPS
induced a relatively permanent elevation of inﬂammatory
factors within the nigrostriatal system and reduced the
number of mature DA neurons in adulthood [85, 86].
Exposure to LPS during critical developmentaltimes was
also found to have protracted consequences that involve
a dramatic long-term sensitization of the inﬂammatory
immune response, such that the neuroinﬂammatory and
neurodegenerativeactionsofpesticidesappliedduringadult-
hood were greatly enhanced [87, 88]. As well, bacterial vagi-
nosis,acommoninfectionduringpregnancy,hasbeenlinked
to boththe developmentofneurological disorders, including
cerebral hemorrhage and cerebral palsy, and with enhanced
levelsof severalproinﬂammatory cytokines, includingIL-1β,
IL-6,andTNF-αinadulthood[89,90].Consistent with these
ﬁndings, our contention has been that early immunogenic
exposure may provoke mild neuroinﬂammation that, over
time, renders neurons vulnerable to the eﬀects of normally
low-grade insults later in life. It may also be that early toxin
exposure causes modest neuronal damage (or a silent lesion)
that only becomes “un-masked” upon later multiple toxin
exposures, again resulting in some threshold of neuronal
vulnerability eventually being breached.
4.1. Role of Proinﬂammatory Cytokines in PD. Cytokines
primarily act through either of three molecular pathways,
involving activation of: (1) NFκB, (2) c-Jun N terminal
kinase (JNK), or (3) janus kinase (JAK) and signal trans-
ducer and activator of transcription (STAT). The latter two
pathways involve the sequential phosphorylation of a series
of intracellular proteins following administration of several
cytokines, including IL-6, IL-10 and IFN-γ, resulting in the
production of factors important for inﬂammatory and neu-
ronal processes [91]. Similarly, the production of immune
and CNS factors, including the inﬂammatory enzyme, COX-
2, occurs following NFκB activation. In particular, IL-1β and
TNF-α trigger the phosphorylation and degradation of the
inhibitory factor, IκB, which normally holds NFκBi na n
inactive state, resulting in its translocation to the nucleus
where it inﬂuences (inﬂammatory) gene expression. In fact,
we found that COX-2 deletion markedly inﬂuenced the
production of cytokines following stressor and endotoxin
exposure [92].
Increasingly, cytokines have been implicated in acute
and chronic neuronal demise [91]. Indeed, clinical studies
revealed augmented levels of proinﬂammatory cytokines
(TNF-α,I L - 6 ,I L - 1 β,I F N - γ) in postmortem brain as well as
in the blood and/or cerebral spinal ﬂuid (CSF) of patients
w i t hs t r o k e ,h e a di n j u r y ,A Da n dP D[ 62, 93–95]. A further
recent study found that PD patients had elevated basal and
LPS-induced blood levels of numerous proinﬂammatory
cytokines, including MCP-1, RANTES,MIP-1α,I L - 8 ,I F N - γ,
IL-1β and TNF-α; and signiﬁcant correlations were observed
between cytokine levels and severity of parkinsonism [96].
Although many of these ﬁndings have been recapitulated in
animal models, it is still uncertain whether these cytokines
primarily play a neuroprotective or neurodestructive role. It
may be that relatively low endogenous cytokine levels act
in a protective capacity to buﬀer against damage related
to death processes, whereas relatively high levels of these
factors contribute to neuronal damage [97]. Indeed, low
levels of cytokines can provoke the release of potentially
beneﬁcial trophic factors (BDNF, GDNF) and free radi-
cal scavengers (MnSOD), but elevated levels can activate
oxidative-inﬂammatory cascades or even induce apoptotic
death (self-destructive programmed death mechanism) [98,
99]. For instance, mice genetically lacking TNF-α receptors
(thereby removing the inﬂuence of low endogenous levels of
TNF-α) were more susceptible to ischemic injury [97]; yet,
administration of exogenous TNF-α a tt h et i m eo fi s c h e m i a
exacerbated neuronal death [100]. Likewise, administration
of the endogenous IL-1 antagonist, IL-1ra, reduced infarct
size in response to middle cerebral artery occlusion and6 Parkinson’s Disease
prevented the accumulation of inﬂammatory inﬁltrates
within the area of damage [101], suggesting a prominent
destructive role for IL-1 in acute cerebrovascular insults.
In eﬀect, the concentration as well as timing of cytokine
exposure likely determines whether primarily protective or
deleterious consequencesarise from these immunotransmit-
ters.
4.1.1. Interferons in PD. Interferons (IFNs) are broadly
dividedintoeithertypeIIFNs,includingtheIFN-αandIFN-
β isoforms, which originated from a common ancestral gene,
or the structurally unrelated type II form, IFN-γ (formerly
called macrophage activating factor). The main signaling
pathways utilized by the IFNs involve the sequential phos-
phorylation of STATs by intracellular JAK protein kinases
(stimulated by ligand-receptor binding). IFN-γ is secreted
predominantly from type 1 helper T lymphocytes (Th1) and
natural killer (NK) cells; yet, recent reports indicate that
the cytokine is also synthesized de novo within the brain
by activated microglia [102]. In contrast, the production of
IFN-α and IFN-β does not appear to be under the control of
speciﬁc cell types, and indeed, most cells appear to be able
to secrete these cytokines in response to viral insult [103].
Although IFNs were originally believed to be exclusively
antiviralsubstances,ithasbecomeapparentthatthecytokine
family is involved in a broad array of immunoregulatory
functions that may either inhibit or promote disease states
within the periphery or CNS (e.g., cancer, chronic microbial
or parasitic infection) [104, 105].
Cancer and hepatitis C patients receiving IFN-α
immunotherapy have been observed in many instances to
develop a PD-like syndrome, including tremors, muscle
rigidity and a generalized paucity of movement [106, 107];
and postmortem examination of PD brains revealed the
presence of MxA (type I IFN-inducible GTPase) in SNc
Lewy bodies and neuronal swellings [108, 109]. Similarly,
recent data suggest an important role for IFN-γ in MPTP
and paraquat animal models of PD [42, 110]. In cor-
roboration of these results, IFN-γ levels are elevated in
the blood [110, 111] and postmortem SNc brain tissue
[112, 113] of PD patients; and a polymorphism in the
gene coding for IFN-γ diﬀerentially modiﬁed the risk of
developing early- or late-onset PD [114]. In addition, levels
of serum and CSF neopterin, a pteridine marker of IFN-
γ-associated immune system activation, are elevated in
PD patients and tend to be highest among those with
more severe symptoms [115]. Indeed, PD patients exhibit
f e w e ri n f e c t i o u se p i s o d e sa n dm a l i g n a n c i e s[ 116, 117],
possibly stemming from enhanced proinﬂammatory IFN
signaling.
Interestingly, a recent study [118] indicated that IFN-γ is
capable of inﬂicting direct excitotoxic neuronal damage by
signaling through a distinct, neuron-speciﬁc receptor com-
plex formed by the IFN-γ receptor and the AMPA receptor
GluR1 subunit. In this way, IFN-γ was observed to induce
dendritic beading in mouse cortical neurons secondary to
an increase in Ca2+ inﬂux, nitric oxide (NO) generation
and ATP depletion [118]. However, most available evidence
suggests that IFN-γ likely inﬂuences neuronal survival and
functioning through its actions on glial cells, particularly
microglia.
While the microglial gene network subject to regulatory
control by IFN-γ is both extensive and diverse (reﬂecting
the pleiotropic nature of IFN-γ and cytokines in general), a
number of positively regulated IFN-γ-responsive genes (i.e.,
those containing GAS (gamma activation sequence), IRF-E
(interferon regulatory factor element), or ISRE (interferon-
stimulated response element) binding sites) encode proteins
implicated in immunoinﬂammatory processes [119, 120];
and hence, may be of particular relevance for neurolog-
ical disorders such as PD. For instance, IFN-γ-associated
microglial JAK/STAT signaling arbitrates (either directly
or indirectly via secondary transcription factors such as
IRF-1) the upregulated or de novo expression of several
genes encoding proteins critical for antigen presentation
to lymphocytes (e.g., MHC class I/II, immunoproteasome
subunits LMP-2 and LMP-7), recruitment and activation
of T cells (i.e., chemokines and adhesion molecules), and
classical pathway-dependent complement deposition [119,
120]. Importantly, many of these same immunologically
relevant factors have been localized to microglia in the
SNc of postmortem PD brains or animals exposed to DA-
targeting neurotoxins [114, 121–123], suggesting that IFN-
γ may be a critical determinant of prospective adaptive
immune responses in PD.
While the pathogenic relevance of adaptive immune
activation in PD has long been debated, a recent study
demonstrated that mice genetically lacking mature CD4+ T
lymphoctyes (but not CD8+ T cells) were protected against
MPTP-induced neurodegeneration [124]. However, in this
study, CD4+ T cell-mediated DA neuronal loss was found
to be dependent on the presence of the TNF ligand family
member, FasL, and not IFN-γ. Of course, these results
do not necessarily preclude a role of IFN-γ in T cell-
mediated dopaminergic neurodegeneration; indeed, FasL
is capable of augmenting inﬂammatory cytokine cascades
from microglia (in addition to directly mediating neuronal
apoptosis), and Fas receptor expression is potently upreg-
ulated in activated microglia following inﬂammatory insult
[125].
In addition to facilitating communication between
microglia and peripheral immune cells, IFN-γ plays a
key role in the activation of oxidative and inﬂammatory
microglial enzyme systems that evolved to protect the host
against pathogenic (and possibly xenobiotic) threats to the
CNS. Indeed, IFN-γ in combination with TNF-α induces
microglial expression of iNOS and several key subunits of
NADPH oxidase [126], as well as the IFN-inducible double-
stranded RNA-activated kinase, PKR [127]. Of course,
NADPH oxidase and iNOS are important mediators of
oxidative-nitrosative stress, and PKR, through its actions on
NFκB, is capable of inducing the PG- and- ROS-producing
enzyme, COX-2 [128]. In fact, pretreatment with the
indole hormone, melatonin, attenuated IFN-γ-a n d -L P S -
mediated expression of COX-2 (and iNOS), and this eﬀect
was attributed to the inhibition of NFκBa c t i v a t i o n[ 129].
Moreover, we recently found that IFN-γ was critical for the
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inﬂammatory (COX-2, NFκB) factors following paraquat
treatment in a mouse model of PD [44]. Importantly,
many of these factors were localized to microglia and their
downregulation in the absence of IFN-γ was associated with
marked neuroprotection against paraquat [44]. Accordingly,
IFN-γ may impact neuronal survival by way of its down-
stream eﬀects on key microglial enzymes implicated in the
elaboration of deleterious inﬂammatory factors (i.e., NO,
ROS, prostanoids).
Likewise, the proinﬂammatory interleukins, IL-7, IL-
15, IL-12, IL1-α,a n dI L - 1 β, are subject to upregulation
by IFN-γ at the gene level in microglia (either directly
or indirectly; e.g., IFN-γ upregulates caspase-1, which in
turn activates IL-1β)[ 120, 130], suggesting that type II
IFN may be an early mover of proinﬂammatory cytokine
cascades. Further, some of these cytokines (including IFN-
γ itself) can skew CD4+ T cell development towards a
Th1/proinﬂammatory phenotype, which has, in fact, been
described in PD [131]. In addition, IFN-γ stimulates TNF-
α production in microglia, presumably through the sensiti-
zation of these cells to antigens (e.g., LPS) and, potentially,
xenobiotic agents (e.g., pesticides) [132]. Importantly, our
laboratory observed that the loss of DA neurons induced
by paraquat treatment was associated with enhanced IL-1β
and TNF-α mRNA within the SNc [44]. Moreover, IFN-
γ-deﬁcient mice failed to show such cytokine elevations
and DA neuronal degeneration in response to the pesticide
[44], indicating once again that IFN-γ might be a pivotal
mediator of toxin-induced inﬂammatory and degenerative
pathology.
IFN-γ signaling may also drive the downregulation of
several ostensibly neuroprotective species in microglial cells,
which could increase neuronal vulnerability to oxidative
and inﬂammatory damage. For instance, IFN-γ dampened
microglial expression of the antiinﬂammatory cytokine,
IL-10 [120], as well as the soluble trophic factor, insulin-
like growth factor (IGF)-1 [119], both of which have been
shown to exert neuroprotective eﬀects in toxin-based animal
models of PD [133–135]. Similarly, Moran and colleagues
[130] reported that the expression levels of osteopontin,
a secretory phosphoprotein with antiapoptotic properties
that can attenuate the neurodegenerative consequences of
stroke [136] and MPTP (at least in common marmosets)
[137],were suppressed inIFN-γ-activated microglia[130].It
ought to be mentioned that genetic ablation of osteopontin
actually mitigated the SNc neuronal loss and striatal DA
denervation following MPTP intoxication in mice, sug-
gesting that osteopontin may, in fact, contribute to DA
neurodegeneration[138].Yet, IFN-γ activity was not directly
assessed in this study (although the MPTP-treated wild-
type mice displayed osteopontin-positive reactive microglia
[138]),and interspecies variability in MPTP sensitivity could
conceivably account for the discrepancy between the studies.
In essence, IFN-γ may contribute to the neurodegenerative
response in PD and its toxin-based animal models by
mediating not only the activation of critical immune eﬀector
mechanisms, butalso thesuppression ofmicroglial processes
more closely aligned with antiinﬂammation and immune
resolution.
In addition to microglia, recent evidence suggests that
astrocytes may mediate some of the central immunomod-
ulatory actions of IFN-γ, potentially through STAT1-
independent signal transduction pathways. For instance,
Hashioka and colleagues [139]f o u n dt h a tI F N - γ (but
not LPS, TNF-α,o rI L - 1 β) caused astroctyes to become
neurotoxic in vitro, reducing the viability of cultured neu-
roblastoma cells. Moreover, inhibition of STAT3 reduced
the neurotoxic potential of these IFN-γ-activated astrocytic
cells [140]. In contrast, several other reports indicated that
IFN-γ signaling in astrocytes mediates primarily neuropro-
tective events. Indeed, IFN-γ-induced activation of astro-
cytes attenuated hippocampal neuronal damage after status
epilepticus (SE) in rats, while neutralization of astrocytic
IFN-γ receptors aggravated SE-induced neuronal pathology
[141].Likewise,combinedIFN-γ and LPStreatmentreduced
apoptosis of hippocampal neurons induced by in vitro
application of beta-amyloid protein, butonly in the presence
of astrocytes [142]. In fact, Ram´ ırez et al. [142]p r o v i d e d
evidence linking this antiapoptotic eﬀect to the upregulated
secretion of the antiinﬂammatory cytokine, transforming
growth factor (TGF)-β,f r o mI F N - γ-a n dL P S - a c t i v a t e d
astrocytes. Thus, while there is much still to be elucidated
regarding thecomplexnatureofbrainIFNsignalinginhealth
and disease (e.g., cellular targets, eﬀector molecules), a large
body of evidence suggests a potentially central role for this
cytokine group, particularly IFN-γ,i nm e d i a t i n ga s p e c t so f
the inﬂammatory repertoire and neurodegenerative process
of PD.
4.1.2. Interleukins and Tumor Necrosis Factor-α in PD.
The cysteine protease, interleukin-converting enzyme
(caspase-1), cleaves the 31–33 kDa precursor, proIL-1, to
form the mature and biologically active IL-1α and IL-1β
cytokines [143]. Some of the synthesized IL-1 is secreted in
a soluble form, but a proportion is retained within the cell
membrane [144]. Both the soluble and membrane-bound
forms of IL-1 are biologically active, particularly with
respect to lymphocyte activation [144]. IL-1 signaling is
dependent upon its type I receptor and the IL-1 receptor
accessory protein, which are located on adjacent portions
of the membrane [145]. Much like IL-1β,T N F - α is a
pleiotropic cytokine, which exerts a wide array of actions
on numerous cell types. For instance, it has physiological
actions on bone osteoclasts (important for rheumatoid
arthritis), mononuclear and polymorphonuclear blood
cells, ﬁbroblasts, skin keratinocytes, insulin sensitive
adipocytes, as well as brain neurons and glial cells [146].
Like other cytokines, TNF-α typically acts locally at the site
of generation; however, small amounts of the cytokine are
found circulating in the bloodstream.
A si nt h ec a s eo fI F N - γ, mounting evidence suggests
a role for ILs and TNF-α in PD. Speciﬁcally, postmortem
analyses of PD brain tissue revealed increased expression
of TNF-α a n di t sr e l a t e dF a sr e c e p t o r ,a sw e l la st h e
cytokines IFN-γ,I L - 1 β and IL-6 [15]. Likewise, in animals,
MPTP induced alterations of proinﬂammatory cytokine
genes, including those encoding IL-1β and TNF-α [147,
148]; and the DA neurotoxin, 6-OHDA, increased levels8 Parkinson’s Disease
of these cytokines within the SNc and striatum [149].
Indeed, an increasing number of studies are beginning
to assess the impact of cytokine manipulations on PD-
like pathology. In this regard, both systemic and central
administration of IL-1β was reported to aﬀect SNc DA
neuronal survival. Indeed, pharmacological inhibition of
IL-1β attenuated the loss of DA neurons provoked by
intra-SNc infusion of LPS together with 6-OHDA injection
[150]. Moreover, direct application of IL-1β augmented the
neurodestructiveeﬀectsof6-OHDAuponculturedmidbrain
neurons [151]. Somewhat surprisingly, chronic adenoviral
induced expression of IL-1β in the striatum also induced a
loss of SNc DA neurons [152], suggesting that the cytokine
can exert damaging eﬀects upon DA terminals that result in
the retrograde destruction of upstream soma. Importantly,
the IL-1β induced loss of neurons was associated with motor
impairment and an enhanced microglial response; and
antiinﬂammatory treatment prevented these eﬀects [152].
Yet, other older studies reported that central infusion of IL-
1β protected DA neurons from 6-OHDA and MPTP toxicity
and induced dendritic branching from residual neurons
following SNc lesion [153, 154]. The discrepancies between
the studies remain to be explained but likely stem from
dose and timing considerations, since, as already mentioned,
some cytokines might have both protective and deleterious
eﬀects depending on their concentration and the state of the
microenvironment in which they act.
Involvement of TNF-α in PD, like IL-1β,i ss o m e w h a t
controversial, with two conﬂicting reports indicating that
TNF-α deletion either protected striatal terminals and
normalized DA levels in MPTP-treated mice [155, 156]
or increased DA metabolism, without necessarily aﬀecting
neuronal survival [157]. Interestingly, in one study there
was no eﬀect of intra-SNc infusion of TNF-α or IL-1β
either alone or together upon neuronal survival [84], but
the source for this outcome is uncertain. More recently,
adenoviral vector mediated long-term expression of TNF-
α within the SNc was reported to provoke a progressive
loss of DA neurons over 28 days that was associated with
irreversible akinesia [158]. Likewise, overexpression of a
dominant negative TNF-α protein (inhibits endogenous
TNF-α) in the SNc ameliorated the loss of DA neurons and
motor impairment induced by 6-OHDA treatment [159].
The cytokines IL-1β and TNF-α typically inﬂuence
central processes through NFκB, a transcription factor that
plays a critical role in the regulation of innate and adaptive
immune reactions, including the mobilization of inﬂam-
matory chemokines and lymphocyte proliferative responses
following infection or traumatic injury [160, 161]. Indeed,
NFκB signaling occurs ubiquitously throughout the brain,
and IL-1β infusion into the lateral ventricles induced the
translocation of NFκB to the nucleus at several brain regions
distal to the site of infusion, including the choroid plexus,
ependymal cells, cerebral vasculature and meninges [162].
NFκB is composed of ﬁve subunits, together with
a nuclear localization signal, which are normally held
in an inactive state by an endogenous inhibitory factor,
IκB. However, exposure to inﬂammatory stimuli triggers
the phosphorylation and consequent degradation of IκB,
resulting in the translocation of NFκB to the nucleus where
it promotes gene expression [160]. Immunological insults
may initiate this NFκB cascade through the provocation
of cytokines, particularly IL-1β and TNF-α,w h i c h ,a f t e r
binding to their cell surface receptors, stimulate kinases that
target IκB for ubiquitination and subsequent proteasomal
degradation [160]. As well, these cytokines may also aﬀect
CNS processes by stimulating NFκB signaling cascades.
NFκBa p p e a r st oh a v ep o t e n te ﬀects upon CNS pro-
cesses important for neuronal survival and plasticity. The
transcription factor may have aneuroprotective role through
the induction of antiapoptotic proteins, such as Bcl-2 and
the antioxidant enzyme, manganese superoxide dismutase
(MnSOD) [163]. Yet, NFκB signaling may also result in
the synthesis or upregulation of inﬂammatory cytokines
and enzymes, ROS, and excitotoxins that can contribute to
neurodegeneration. For instance, iNOS expression within
microglia and astrocytes is readily provoked by NFκB
activation following exposure to cytokines, such as IL-
1β or IL-12 [164, 165]. Similarly, stressor exposure may
contribute to neurological pathology by aﬀecting NFκB-
mediatedproductionofoxidativeradicalsgiventhatrestraint
stress was shown to promote neuronal excitotoxicity in rats
that was associated with enhanced TNF-α release and NFκB
mediated activation of iNOS and COX-2 [166]. Ultimately,
a host of factors, including the chronicity and type of
inducing stimulus, likely inﬂuence whether NFκBa c t i v a t i o n
has protective or detrimental eﬀects upon neuronal survival
or functioning.
4.2. Cyclooxygenase-2 in PD. Cyclooxygenase, present in the
CNS as COX-1, COX-2 and COX-3 isoforms, is an integral
plasma membrane glycoprotein critically involved in the
production of PGs from arachidonic acid (AA). The ﬁrst
step in PG biosynthesis involves the conversion of glyc-
erophospholipid into free AA by phospholipase A2, which is
ubiquitouslypresentinallbraintissuesandwhoseexpression
is upregulated by infection or injury [167]. Thereafter,
COX metabolizes AA into PGG2 and then PGH2, which
is transformed further by terminal synthases into speciﬁc
PG species. AA is preferentially metabolized by COX-2 to
PGE2 (the most abundant PG), whereas COX-1 produces
only small amounts of this prostanoid [168]. In addition to
these biologicallyactive lipid mediators, substantial amounts
of ROS are formed during the COX-mediated peroxidative
reduction of PGG2 to PGH2.
Within the CNS, all three COX isozymes are expressed
and heterogeneously distributed in several discrete neural
populations where they mediate a diverse range of functions
in health and disease. COX-1 may be generally described
as a constitutive “housekeeping” enzyme, supplying PGs at
(low)levelsrelevantfortheregulationofmyriad homeostatic
brain processes (e.g., cerebral blood ﬂow) [167]. Much
less is known regarding the functions of COX-3 (which
appears to be splice variant of COX-1);however, preliminary
evidence suggests that the recently discovered COX isozyme
may be important for species-speciﬁc febrile responses and
the processing of painful stimuli [169, 170]. Contrastingly,
under normal physiological conditions COX-2 partakesParkinson’s Disease 9
in a diverse array of response-related activities, includ-
ing synaptic plasticity and signaling, neurotransmission,
memory consolidation during rapid eye movement (REM)
sleep, membrane excitability, and gene expression [167,
171]. Indeed, the COX-2 gene promoter contains multiple
regulatory elements (e.g., that recognize glucocorticoids,
cytokines, NFκB, cAMP, and CREB) that either enhance or
suppress COX-2 transcription [171, 172].
Not surprisingly, COX-2 is subject to induction by
a variety of inﬂammatory stimuli, many of which (e.g.,
cytokines, ROS) have been implicated in the generalized
activation of microglial cells in response to and as a corollary
of acuteinﬂammation associated with infection, brain injury
or neurodegeneration. For instance, administration of the
bacterial endotoxin, LPS, or the DA toxin, MPTP, elicited a
marked increase in microglial COX-2 expression [173, 174].
Yet, COX-2 is also present in neurons, and is similarly
induced during inﬂammatory episodes [17].
As is the case for proinﬂammatory cytokines, substantial
evidence indicates that COX-2 may play an important role
in the neurodegenerative process of PD and its animal
models. In this regard, COX-2 expression was elevated in
microglial cells [175] and DA neurons [176] within the SNc
of postmortem PD brain (although the latter study failed
to detect increased COX-2 in microglia). Likewise, MPTP-
intoxicated mice displayed augmented COX-2 immunoreac-
tivity within both SNc neurons [176] and microglia [174],
and pharmacologic inhibition or genetic ablation of COX-
2 prevented the loss of DA neurons following exposure to
MPTPor6-OHDA[177,178].Similarly,Yang and colleagues
[179] recently demonstrated the crucial role of COX-2 in
paraquat-induced neurotoxicity in vitro, and our group
found that mice genetically lacking COX-2 were resistant to
thePD-likeneurological(nigrostriatal DAtransmission) and
behavioural (bradykinesia) eﬀects of the pesticide [180].
Interestingly, several epidemiological reports indicated
that NSAIDs, which act primarily to inhibit COX-2 (but
also scavenge ROS and RNS [181, 182]), might either
prevent or delay PD onset [183–185]. Yet, numerous other
contemporaneous studies have failed to ﬁnd compelling
evidence of a protective role of such drugs in PD [186–
188]. Although consensus remains elusive, a recent meta-
analysisevaluatingtheimpactofNSAIDsonPDriskrevealed
that regular, long-term use of nonaspirin NSAIDs (but not
aspirin oracetamenophen) reducedPDincidencebyroughly
15% [189].
Inﬂammatory PG signaling, which is mediated in large
part by PGE2, constitutes a primary mechanism by which
COX-2 might come to inﬂuence neuronal functioning and
survival in neurological illness. For instance, PGE2 signal-
ing through the EP1 receptor provoked cAMP-dependent
apoptosis of hippocampal neurons [190], and pharmaco-
logical blockade of EP1 receptors completely prevented DA
neuron loss following 6-OHDA treatment in embryonic rat
mesencephalic primary neuronal cultures [191]. Emerging
evidence indicates that PGE2 may act in an autocrine
or paracrine manner to augment the COX-2-dependent
microglial (and possibly neuronal) production of further
prostanoid species [192, 193]. Indeed, PGE2 is capable of
promoting the inherent transcriptional activities of NFκB
[194], which can then exert trans-activational control over
the COX-2 gene promoter [195]. In this way, PG signaling
between neural cells might serve in the recruitment of
otherwise quiescent microglia and augment the synthesis
and release of inﬂammatory mediators, includingfurther PG
species, from heretofore activated microglial cells [174, 196].
This, in turn, would of course be expected to exacerbate
ongoing DA neurodegeneration.
It ought to be underscored, however, that despite
the evidence seemingly linking microglial COX-2 to DA
neuronal death, there remains considerable controversy
surrounding the relative contribution (and functional rele-
vance) of microglial versus neuronal COX-2 in PD. Indeed,
several reports indicated that a JNK-mediated induction
of COX-2 in neurons but not microglia is critical for DA
neuron cytotoxicity following MPTP treatment [197, 198].
Moreover, Teismann and colleagues [176]p r o v i d e dc o m -
pellingevidencefavoringtheimportanceofcell-autonomous
oxidative processes (i.e., COX-2-derived ROS, DA-quinone
formation) overPG-mediated inﬂammatory onesinCOX-2-
dependent neurodegeneration. Similarly, increased neuronal
COX-2 activity has been implicated in paraquat-induced
neurotoxicity [179]; and, while the regulatory mechanisms
subserving neuronal COX-2 induction by paraquat have
yet to be deﬁned, there is reason to believe that JNK
pathway activation may be critical, given the importance
of JNK in mediating the ROS-dependent in vitro and
in vivo neurodegenerative eﬀects of paraquat upon DA
neurons [199, 200]. In contrast, the ﬁndings of a recent
study in monkeyssuggested that neuronal COX-2 expression
was not associated with increased susceptibility to MPTP-
induced neurodegeneration [201]; and Boyd et al. [202]
observed robust strain-speciﬁc diﬀerencesin neuronal COX-
2 responses to MPTP in mice. In short, while the cellular
and molecular determinants of brain COX-2 expression
in neurological illness remain somewhat controversial, it
is relatively certain that inﬂammatory and/or oxidative
responses mediated by inducible COX-2 activity contribute
to the neurodegenerative process of PD and its animal
models.
It is also worth noting that COX-2, in addition
to mediating potentially deleterious proinﬂammatory and
prooxidative responses, appears to promote inﬂammatory
immune resolution both in the CNS and the periphery.
Consistent with this notion, even as PGE2 signaling through
EP1 receptors is implicated in COX-2-mediated neuro-
toxic events, EP2/EP4 receptor signaling often mediates
prosurvival responses. For instance, stimulation of EP2
and/or EP4 receptors prevented neuronal death following
excitotoxic/ischemic insult [203, 204] and antagonized the
neurotoxic eﬀects of beta-amyloid [205], 6-OHDA [206]
and LPS [207]. More generally, multiple COX-2-derived
prostanoids seem able to promote central immunosup-
pressive/antiinﬂammatory responses by directing a reduc-
tion in proinﬂammatory factors (e.g., TNF-α,N O )o ra n
increase in antiinﬂammatory ones (e.g., IL-10, BDNF) [208,
209]. Further, other nonprostanoid COX (and lipoxygenase)
derived lipid mediators, particularly the recently discovered10 Parkinson’s Disease
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Figure 1: Conceptual overview of how environmental toxins may provoke DA neurodegeneration in Parkinson’s disease and its animal
models. Chronically activated microglia are integral mediators of pathology, synthesizing and secreting a plethora of prooxidant and
proinﬂammatory factors, several of which (e.g., IFN-γ, PGs) may form positive feedback loops to stimulate the production of further
inﬂammatory/oxidativefactors (e.g., ROS, PGs) by microglial cells. Severalmutually nonexclusive mechanisms exist whereby toxin-induced
microglial release of prooxidant/inﬂammatory agents may lead to DA neurodegeneration; these include lipid peroxidation, DNA damage
and the activation of intracellular apoptotic pathways. Additionally, there is evidence to suggest that both adaptive immune responses (e.g.,
T cell-dependent) and cell-autonomous oxidative processes (e.g., DA-quinone formation)may contribute to DA neuronal loss in PD.
DHA-derived docosanoids (resolvins and neuroprotectins),
appeartoantagonizetheinﬂammatory actionsofCOX-2and
curb proinﬂammatory CNS responses more generally (e.g.,
inhibit NFκB, up/downregulate anti/proapoptotic proteins,
suppress cytokine synthesis, modulate leukocyte traﬃcking)
[210, 211]. It is conceivable that variations in COX-2
signaling that favor EP2/EP4 receptor involvement, and
hence DA neuronal survival, might occur in conjunction
with certain cytokine proﬁles and inﬂammatory responses
following DA neuron injury. It might even be the case that
t h en a t u r eo ft h ei n ﬂ a m m a t o r yr e s p o n s e( i n v o l v i n gC O X - 2
and cytokines) might vary over time following insult, such
that there may be a waxing and waning of neuroprotective
versus neurotoxic mechanisms engaged.
5.Conclusionsand FutureDirections
The ﬁndings discussed in this paper provide support for
a role of proinﬂammatory factors, particularly cytokines
(IFN-γ,I L - 1 β,T N F - α) and inducible enzymes (COX-2),
as well as their associated inﬂammatory signaling pathways
(e.g., JAK-STAT, NFκB, and MAP kinases), in the prodeath
processes operating in PD (see Figure 1); and hence, support
the contentionthat antiinﬂammatory treatments might have
general clinical utility for PD and other neurodegenerative
conditions. Given the complexities of the inﬂammatory
response, future eﬀortswould be wise to focusondeveloping
more selective immune modulatory agents that target spe-
ciﬁccytokines(andotherinﬂammatory mediators)atcertain
stages of PD. This is not to say that such antiinﬂammatory
agents should replace conventional treatments, rather these
novel drugs might be useful as adjuncts or “add-ons” to
existing therapies. Indeed, owing to the multifaceted nature
of and likely multiple mechanisms involved in neurological
illnesses such as PD, a multipronged drug approach seems
reasonable.
While it seems undeniable that the inﬂammatory
immune response plays a crucial role in dopaminergic loss
and the clinical symptoms observed in PD, it remains to
be determined whether neuroinﬂammation is most relevant
to disease process genesis or, rather, is secondarily induced
following neuronal injury and thus more critically aligned
with shaping the evolution of pathology over time. The
emerging picture does suggest, however, that one important
mechanism underlying DA neuronal loss in toxin-based
animal models of PD involves the (chronic) activationParkinson’s Disease 11
of microglial cells, which through the actions of proin-
ﬂammatory cytokines and inducible enzymes, mediates
the production of damaging oxidative radicals and soluble
inﬂammatory mediators.
While excessive microglial and proinﬂammatory cytok-
ine driven inﬂammation can mediate profoundly deleterious
CNS consequences, including DA neurodegeneration in PD
and its toxin-based animal models, it should be underscored
that many aspects of immune surveillance and glial activity
are essential for brain health. Indeed, routine traﬃcking
of T lymphocytes into the CSF and microglia-neuron and
microglia-astrocyteinteractionsarecriticalforprotectingthe
CNS from invading pathogens, regulating extracellular ﬂuid
composition, removing potentially harmful cellular debris,
and promoting adaptive neuroplastic responses to CNS chal-
lenge. Hence, a delicate balance exists between the positive
and negative aspects of immune-inﬂammatory signaling in
the CNS.Problemslikelyarise when environmental toxinsor
other external challenges overwhelm and usurp the natural
plasticity of neuroinﬂammatory responses to promote an
abnormal, hyperactive microglial state that encourages
overzealous oxidative/inﬂammatory factor release.
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